IL6 and congenital rubella syndrome: Another therapeutic agent is a monoclonal antibody targeting IL-6, siltuximab, which has a higher affinity for IL-6 than tocilizumab for the IL6 receptor, making it a potential smoke screen for CRS treatment (126).